TTOP Secures $1.3M in Seed Funding to Revolutionize Drug Development with True Tissue On Platform

TTOP - True Tissue On Platform is excited to announce that it has successfully raised $1,300,000 in funding to further its mission of revolutionizing drug development through its innovative microphysiological platform. TTOP’s modular and versatile approach addresses the critical challenges faced by the pharmaceutical industry, which often sees an astonishing average investment of $2 billion and over a decade of research and development for a new drug that has an 80% failure rate in clinical trials. Traditional in vitro models fall short in their predictive capabilities, and animal models, while still in use, are fraught with ethical dilemmas and do not always translate effectively to human outcomes. TTOP aims to change that narrative by providing advanced in vitro systems that mimic complex human pathophysiological conditions, enhancing the predictivity of preclinical results. With this funding, TTOP plans to accelerate the development and integration of its user-friendly platform into biotechnology research, allowing for a more sustainable, ethical, and animal-free approach to discovering new therapeutics. This investment not only reinforces the importance of ethical considerations in drug development but also aligns with the pressing need for efficient and safer alternatives to current methodologies. As TTOP continues to innovate, it remains steadfast in its commitment to improving the drug development ecosystem, ultimately benefitting patients and researchers alike by fostering a more reliable path to market for new medicines.